Study evaluates amyloid PET in patients with suspected Alzheimer's disease | Study sheds light on how sugar drives cancer cell growth | Tumors found to recur thanks to cancer cells that hide from immune system
October 20, 2017
CONNECT WITH SNMMI
News for nuclear medicine and molecular imaging professionals
Imperial College researchers found that amyloid PET with F-18 florbetapir led to changes in diagnosis among patients with suspected Alzheimer's disease who didn't have amyloid buildup in the brain, as well as reduced the use of invasive tests to identify amyloid, such as cerebral spinal fluid analysis, among those with uncertain diagnosis. Amyloid PET may be most beneficial in evaluating younger patients with suspected early-onset dementia, whose symptoms may be different from those of older patients with the disease, researchers wrote in the Journal of Neurology, Neurosurgery & Psychiatry.
Cancer cells readily consume sugar, which leads to a cycle of cancer development and growth, according to a study in Nature Communications. The nine-year research project shows how sugar connects with Ras proteins, which control cell growth and differentiation and are found in large quantities in tumors.
Some cancer cells can hide from the immune system after successful cancer treatment and form new tumors that send signals hiding them from immune cells, according to a study of mice published in Cancer Immunology Research. "It is becoming increasingly clear that the immune system is at the core of the puzzle of how we can treat cancer more effectively," said Kevin Harrington, co-author of the study.
Providing early palliative care for patients with newly diagnosed mesothelioma did not improve quality of life, survival, mood or anxiety, researchers reported at the 18th World Conference on Lung Cancer. Researcher Dr. Fraser Brims said one reason could be that these patients already had excellent care and adding palliative care did not make much difference at that level.
Cerveau Technologies has entered an agreement with Janssen Pharmaceuticals for research studies using its F-18 MK-6240, an investigational PET tracer for imaging neurofibrillary tangles in the brain, as a biomarker to diagnose neurodegenerative diseases and evaluate new treatments for them.
Bristol-Myers Squibb's marketing application for breakthrough therapy-tagged Opdivo, or nivolumab, to be used as a treatment for patients with high-risk, advanced melanoma, has been granted priority review status by the FDA.
A study in the journal Family Medicine found the psychosocial BATHE intervention, which stands for background, affect, trouble, handling and empathy, increases hospital inpatient satisfaction scores. The technique lets patients share psychological or life problems with clinicians, and data showed patients who participated gave their physicians an average score of 4.77, compared with a 4.0 score given by patients receiving standard care.
A bipartisan agreement struck by Sens. Lamar Alexander, R-Tenn., and Patty Murray, D-Wash., to stabilize Affordable Care Act markets by funding cost-sharing reduction payments through 2019 experienced major setbacks Wednesday after several key congressional Republicans said they opposed the proposal and President Donald Trump withdrew his support. The future of the deal is now in doubt with only a few senators announcing support for the plan, including Sens. John McCain, R-Ariz., Susan Collins, R-Maine, and Lisa Murkowski, R-Alaska.
Forty-one percent of reported health data breaches in the first nine months of 2017 were attributed to unintended data disclosure, such as accidentally leaving a server open to the public or sending an email containing personal health information to the wrong recipient, which was also the leading cause of such incidents in 2016 and 2015, according to the Beazley Breach Insights report. Hacking or malware incidents were the second most common cybersecurity issue at 19%, followed by insider incidents at 15% and physical loss at 8%, the report stated.
Abstracts are currently being accepted for the 2018 ACNM Annual Meeting, taking place Jan. 25-27 in Orlando, Fla. Young professionals are invited to submit clinical or scientific abstracts on aspects of clinical and basic science in nuclear medicine, correlative imaging in nuclear medicine and radiology, nuclear pharmacy and physics, nuclear cardiology, radionuclide therapy, or quality and safety in nuclear medicine. Get started today.
Whether you're looking to build your general CT knowledge or preparing to sit for the ARRT (CT) and/or NMTCB (CT) exams, the new CT+ Review and Essentials course provides you with the comprehensive didactic education you need to succeed. This 18-module, 17-credit course focuses on contrast administration, cross-sectional anatomy, physics and instrumentation, radiation safety, dosimetry and more! Plus, a postcourse mock exam lets you assess what you've learned! Get started today.
I like work; it fascinates me. I can sit and look at it for hours.
Jerome K. Jerome, writer and humorist
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at email@example.com.